Central Nervous System (CNS) Therapeutics Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The Central Nervous System (CNS) Therapeutics market size was estimated at USD 104.70 billion in 2023 and is projected to reach USD 159.84 billion in 2030 at a CAGR of 6.23% during the forecast period 2023-2030.

Central Nervous System (CNS) therapeutics are drugs that are used to treat diseases of the brain and spinal cord. They are a broad class of drugs that include many different types, each with its own specific mechanism of action. The CNS includes the brain and spinal cord and plays a crucial role in controlling various bodily functions and behaviours. CNS therapeutics are used to treat a wide range of neurological and psychiatric conditions. Some common CNS therapeutics include antidepressants, which are used to treat depression and certain anxiety disorders, anti-epileptics, which are used to control seizures and are essential in the treatment of epilepsy, antipsychotics, which are used to manage psychotic disorders like schizophrenia and bipolar disorders, etc. CNS therapeutics play a crucial role in improving the quality of individuals with various neurological and psychiatric conditions.

The CNS Therapeutics market can be segmented based on disease into neurovascular diseases, trauma, mental health, degenerative disease, infectious diseases, cancer, and others. On the basis of drug class, the market is bifurcated into analgesics, antidepressants, anaesthetics, anti-parkinson drugs, anti-epileptics, and other drug classes. Based on distribution channel, the market is bifurcated into hospital-based pharmacies, retail-based pharmacies and online pharmacies. Based on age group, the market is segmented into paediatric, adult, geriatric, and lastly, based on region, its segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America. The CNS therapeutics market is a dynamic and growing market. The market is expected to continue to grow in the forecast period due to increasing prevalence of CNS diseases, rising demand for effective treatments and the development of new and innovative CNS therapeutics.

The degenerative disease is expected to dominate the market in this segment. This growth can be attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis. In addition to this, the rise in drug development pipeline, and the potential of this segment open opportunities for clinical studies, product launches, and strategic collaborations is further expected to drive the market during the forecast period.

COVID-19 Pandemic had a considerable impact on the CNS therapeutics market. As the COVID-19 cases increased worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. However, it was noted that COVID-19, though severely affected the respiratory system, had effects on central and peripheral systems. Moreover, clinical trials on the repurposing of anti-depressants for COVID-19 had increased during the pandemic phase and this had a significant impact on the CNS therapeutics market.

Delvens Industry Expert's Standpoint

The CNS therapeutics market is expected to grow during the forecast period. This growth can be attributed to factors such as increased prevalence of CNS diseases due to factors such as aging population, increasing environmental pollution and changing lifestyle. Moreover, the rising demand for effective treatment for CNS diseases is also rising. This is due to the increasing awareness about the availability of effective treatments and the increasing willingness of patients to pay for these treatments. In addition to this, there is a growing focus on the development of new and innovative CNS therapeutics. This is due to the increasing understanding of the molecular basis of CNS diseases.

Market Portfolio

Key Findings

• The market is bifurcated based on disease into neurovascular diseases, trauma, mental health, degenerative disease, infectious diseases, cancer, and others. The degenerative disease is expected to dominate the market in this segment. This growth can be attributed to the increasing prevalence of Alzheimer's disease, Parkinson's disease, and multiple sclerosis. In addition to this, the rise in drug development pipeline, and the potential of this segment open opportunities for clinical studies, product launches, and strategic collaborations is further expected to drive the market during the forecast period.
   
• Based on drug class, the market is segmented into analgesics, antidepressants, anaesthetics, anti-Parkinson drugs, anti-epileptics, and other drug classes. The antidepressants segment led the CNS therapeutics market in this segment and is expected to dominate the market during the forecast period due to increasing prevalence of depression and the rising demand for effective treatments.
   
• Based on distribution channel, the market can be segmented into hospital-based pharmacies, retail-based pharmacies and online pharmacies. The hospital-based pharmacies dominated the market in this segment due to rapid increase in prevalence of CNS diseases in geriatric population, technological advancements and lifestyle changes.
   
• By age group, the market is segmented into paediatric, adult and geriatric. The geriatric population dominated the market in this segment and is expected to dominate the market during the forecast period. This is due to the rapid increase in CNS diseases such as Alzheimer’s in the geriatric population.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. In North America, increased usage of technology in the health care sector along with the increasing product launches, owing to the rising burden of CNS disease and the rising level of research and development are driving the growth of the market.

Regional Analysis

North America to Dominate the Market

• North America is estimated to account for the largest market share during the forecast period. The increased usage of technology in the healthcare sector in the United States, along with the increasing product launches, owing to the rising burden of the central nervous system disease, and the rising level of research and development are driving the growth of the market.
   
• Moreover, the rising burden of neurodegenerative diseases such as Alzheimer’s within the region is expected to contribute to the market growth during the forecast period.

Competitive Landscape

• Biogen
• Otsuka Pharmaceutical Co. Ltd
• Eli Lilly and Company
• Merck KGaA
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Johnson & Johnson Private Limited
• Pfizer Inc.
• GlaxoSmithKline PLC
• Shire PLC
• Cipla Inc.
• Lupin Ltd
• Glenmark Pharmaceuticals
• AbbVie Inc.
• BIAL Group
• Bristol-Myers Squibb
• Allergan Plc
• Alkermes Plc

Recent Developments

• In June 2022, CNS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its ongoing potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine (Gleostine) administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
   
• In January 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka); its subsidiary Otsuka America Pharmaceutical, Inc.; and Lundbeck, Inc., a U.S. subsidiary of H. Lundbeck A/S in Denmark, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI (brexpiprazole) for the treatment of schizophrenia in paediatric patients 13 to 17 years of age.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Central Nervous System (CNS) Therapeutics Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope